

JPM Gbl Healthcare C Dis NAV £

Fund Information

Sector

Equity - Pharma Health & Biotech

Manager's Name

Anne Marden
Matthew Cohen
Laurence McGrath

Date Manager Appointed

Oct 2009

Launch Date

Mar 2015

Fund Size (£m)

£4801.90

Yield* (See page2)

0.00 %

XD Dates

Sep 10

Last Distribution

10/09/20 (XD Date)
24/09/20 (Pay Date)
0.02(Distribution)

OCF

1.01 %

Fund Aim

To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally.

Sector: Equity - Pharma Health & Biotech

Performance



■ JPM Gbl Healthcare C Dis NAV £
■ Equity - Pharma Health & Biotech

Discrete Performance - 12 months to 31/12/20

	2020	2019	2018	2017	2016
Fund	20.37	18.41	9.04	10.79	1.78
Stock Sector Average	23.57	25.02	-2.69	14.94	-9.92

Cumulative Performance to 30/06/21

	1 Yr	2 Yrs	3 Yrs	4 Yrs	5 Yrs
Fund	13.26	37.18	53.58	64.87	88.90
Stock Sector Average	21.96	45.54	53.78	62.14	84.58

Performance Analysis - Annualised 3 years

	Growth Rate %	Volatility	Alpha	Beta	Sharpe
Fund	15.37	14.97	3.04	0.79	0.79
Stock Sector Average	15.42	16.25	0.00	1.00	0.73

Morningstar Analyst Rating


N/A

FE Crown Rating




JPM Gbl Healthcare C Dis NAV £

Fund Composition



	(%)
North American Equities	76.60
International Equities	13.50
Money Market	5.10
UK Equities	2.80
Global Emerging Market Equities	1.10
Japanese Equities	0.70
Asia Pacific ex Japan Equities	0.20



	(%)
North America	76.60
Europe & Middle East	13.50
Money Market	5.10
UK	2.80
Global Emerging Markets	1.10
Japan	0.70
Pacific ex-Japan	0.20

Largest Holdings

Holdings	(%)
UNITEDHEALTH GROUP INC	7.10
Cigna Corp ORD	4.20
JOHNSON & JOHNSON	3.60
THERMO FISHER SCIENTIFIC INC	3.50
BRISTOL MYERS SQUIBB SA	3.50

Holdings	(%)
LILLY (ELI) & CO	3.30
ROCHE HLDG AG	3.30
NOVARTIS AG	3.30
CENTENE CORP(DEL)	3.00
AMGEN INC	2.80

* Data supplied by fund managers regarding fixed interests funds may not specify yield type. As the provision of redemption yield is an FCA regulatory requirement Novia assumes these are used.

Important Information

Performance details and yields are as at 30/06/2021. Performance figures are inclusive of net reinvested income. Source: FE. This document is designed only for professional investors and experienced advisers. The value of investments and the income gained may fluctuate. Investors may not get back the full amount invested. Past performance is not a guide to the future.